BioNTech


Management focus is on a strong balance sheet

20/11/23 -"After the fairly decent Q3 results and the guidance cut on costs, a mix of lower operating costs, higher interest income (again) and a lower tax rate have all driven an upgrade to our 2023 EPS ..."

Pages
60
Language
English
Published on
20/11/23
You may also be interested by these reports :
28/10/25
The Q3 operating profitability was slightly behind the street’s expectations, though sales were in line with consensus. The quarterly performance was ...

24/10/25
The Q3 operating profitability came in considerably ahead of the street’s estimates, though sales met expectations. The performance was driven by ...

23/10/25
The Q3 sales missed expectations by a small margin; however, the management upgraded its 2025 earnings outlook. The Pharmaceuticals segment was again ...

23/10/25
Lonza’s strong Q3 commentary reaffirmed its commitment to meeting the 2025 guidance, boosting investor sentiment. While operational figures were not ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO